Aripiprazole was added to the VA National Formulary in April 2004 but was available in the VA through a nonformulary
request since its FDA approval in November 2002 (Personal communication 2014).
In addition, the association recommends PBMs, plans, and employers temporarily cover nonformulary
drugs as if they are on formulary during the first 30 days after a formulary list is changed.
The DOC is spending millions of dollars on nonformulary
We're seeing traditional three-tier drug plans (generic, formulary brand and nonformulary
brand) with a preferred and nonpreferred category in each of the three bands.
The medical program director is responsible for the supervision and clinical support of the medical providers and midlevel providers working within RIDOC, approving consultants, outside referrals, nonformulary
medications and labs, medical furloughs, medical complaints and outside elective medical care.
An unintended consequence could be, ironically, that it may decrease access for women because if contraceptives are reclassified as nonformulary
drugs by going over the counter, can insurance companies say they're not going to cover them as they don't cover aspirin, for instance?
Outside documentation that supports a current nonformulary
medication regimen can be crucial to a smooth transition of care.
In fact, in the president's budget submission for FY 2013, (57) DoD advanced this exact concept, proposing to raise copays for brand and nonformulary
refills but keep copays for generic refills through home delivery and all refills made at the MTF free.
For example, between 2000 and 2011, the average copayment for brand name (preferred) drugs on a plan's formulary increased from $15 to $29, while the average copayment for nonformulary
(nonpreferred) brand name drugs increased from $29 to $49.
It has increasing copays for generic, formulary brand-name and nonformulary
I read Richard Hoover's column ("A Medication Education," Reasons & Remarks, redivivus, June 2010) about formulary and nonformulary
medication very thoroughly.
DOD's decision to designate a drug as either formulary or nonformulary
is based on the drug's clinical and cost-effectiveness relative to the other drugs in its therapeutic class.